These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Reversal of caldesmon function by anti-caldesmon antibodies confirms its role in the calcium regulation of vascular smooth muscle thin filaments.
    Author: Marston SB, Redwood CS, Lehman W.
    Journal: Biochem Biophys Res Commun; 1988 Aug 30; 155(1):197-202. PubMed ID: 2970847.
    Abstract:
    Direct evidence that caldesmon is the Ca2+-regulated inhibitory component of native smooth muscle thin filaments is provided by studies using caldesmon-specific antibodies as antagonists. The antibodies reverse caldesmon inhibition of actomyosin ATPase and abolish Ca2+-regulation of native aorta thin filament activation of myosin ATPase. This effect is a result of antibody binding to the caldesmon on the filament thereby inactivating it and not due to antibody-induced caldesmon dissociation from the filament. The antibodies, however, neutralise caldesmon only in systems using skeletal muscle myosin and not in those using smooth muscle myosin; this implies that smooth muscle myosin prevents appropriate antibody binding to caldesmon perhaps because smooth muscle myosin binds to caldesmon thus preventing access of antibody to antigenic sites.
    [Abstract] [Full Text] [Related] [New Search]